In the context of RMS, the TME is enriched with CD4+ CTLs that can be stimulated by fusion peptides derived from the PAX-FKHR fusion protein in RMS cells, leading to the lysis of tumor cells [50]. The gene discussed is FOXO1; the disease is neoplasm.